TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7527100

Group type: EXPERIMENTAL
Intervention: Trandolapril 0.5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Trandolapril 2 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Trandolapril 4 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Trandolapril (0.5-4 mg range)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Trandolaprilat
Number of subjects: 12
Study: 3338365

Group type: EXPERIMENTAL
Intervention: metoclopramide and cimetidine
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo and cimetidine
Number of subjects: 20
Study: 4821036

Group type: EXPERIMENTAL
Intervention: Chelation therapy
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control
Number of subjects: 18
Study: 29477665

Group type: EXPERIMENTAL
Intervention: vemurafenib 960 mg tablets twice daily for 52 weeks
Number of subjects: 498

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 498
Study: 27689427

Group type: EXPERIMENTAL
Intervention: EXPECT questionnaire (18-item draft)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Short form of the EXPECT questionnaire (3-item)
Number of subjects: 322
Study: 25795646

Group type: EXPERIMENTAL
Intervention: Fingolimod 0.5 mg/day
Number of subjects: 920

Group type: EXPERIMENTAL
Intervention: Fingolimod 1.25 mg/day
Number of subjects: 920

Group type: COMPARATOR
Intervention: Placebo to Fingolimod 0.5 mg/day
Number of subjects: 920

Group type: COMPARATOR
Intervention: Placebo to Fingolimod 1.25 mg/day
Number of subjects: 920
Study: 23764639

Group type: EXPERIMENTAL
Intervention: Full PopART intervention strategy including home-based HIV testing, linkage to care, universal antiretroviral therapy, voluntary medical male circumcision, diagnosis and treatment of STIs, behavioral counseling, and condom distribution.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: PopART intervention strategy
Number of subjects: 21
Study: 21940595

Group type: EXPERIMENTAL
Intervention: FR-MDM (fortified rice midday meal with 19 mg Fe)
Number of subjects: 140

Group type: COMPARATOR
Intervention: UFR-MDM (unfortified rice midday meal)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: FR-MDM
Number of subjects: 140

Group type: COMPARATOR
Intervention: UFR-MDM
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: FR-MDM and UFR-MDM
Number of subjects: 140
Study: 19034753

Group type: EXPERIMENTAL
Intervention: SNRI duloxetine
Number of subjects: 130
Study: 17211107

Group type: EXPERIMENTAL
Intervention: Anterior-posterior electrode position
Number of subjects: 103

Group type: COMPARATOR
Intervention: Anterior-lateral electrode position
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 103
Study: 15084194

Group type: EXPERIMENTAL
Intervention: pH-stat
Number of subjects: 30

Group type: COMPARATOR
Intervention: alpha-stat
Number of subjects: 30
Study: 11160635

Group type: EXPERIMENTAL
Intervention: Caffeine (400 mg/70 kg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nicotine (1.5 mg/70 kg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nicotine (0.75, 1.5, and 3.0 mg/70 kg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Caffeine (150 mg/70 kg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Caffeine and Nicotine
Number of subjects: 9
Study: 9637143

Group type: EXPERIMENTAL
Intervention: Prostate cancer screening
Number of subjects: 1126

Group type: EXPERIMENTAL
Intervention: Prostate biopsy
Number of subjects: 1126

Group type: EXPERIMENTAL
Intervention: Digital rectal examination
Number of subjects: 1126

Group type: EXPERIMENTAL
Intervention: Transrectal ultrasound
Number of subjects: 1126

Group type: COMPARATOR
Intervention: Nonparticipants
Number of subjects: 1126
Study: 8069732

Group type: EXPERIMENTAL
Intervention: Subcutaneous erythropoietin (150 U/Kg/wk to 180 U/Kg/wk)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Intravenous erythropoietin (75 U/Kg/wk to 90 U/Kg/wk)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Subcutaneous erythropoietin (for CAPD patients)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Subcutaneous and intravenous erythropoietin (various doses)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Subcutaneous erythropoietin
Number of subjects: 65
Study: 3056073

Group type: EXPERIMENTAL
Intervention: 4-Methylpyrazole 10 mg/kg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 4-Methylpyrazole 20 mg/kg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 4-Methylpyrazole 50 mg/kg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 4-Methylpyrazole 100 mg/kg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 15660797

Group type: EXPERIMENTAL
Intervention: Optimized sensor settings (OSS)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Default sensor setting (DSS)
Number of subjects: 54
Study: 31238955

Group type: EXPERIMENTAL
Intervention: HEALTH intervention
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: HEALTH training curriculum
Number of subjects: 504

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 504
Study: 27287389

Group type: EXPERIMENTAL
Intervention: 21mg/day nicotine patch and four brief behavior counseling sessions over 8 weeks
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Anhedonic status (hedonic vs. anhedonic)
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Anhedonia
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: Nicotine patch therapy
Number of subjects: 525
Study: 26323736

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Group D, n=20; 0.5μgkg(‐1)h(‐1))
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propofol (Group P, n=20; 3mgkg(‐1)h(‐1))
Number of subjects: 40
Study: 23612399

Group type: EXPERIMENTAL
Intervention: Neuromidin (ipidacrinum) therapy for 2 months
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (37 people without stroke history)
Number of subjects: 53
Study: 21528605

Group type: EXPERIMENTAL
Intervention: Cupping for 25-30 min
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cupping for 15 min
Number of subjects: 60
Study: 19307500

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus gemcitabine and erlotinib
Number of subjects: 607

Group type: COMPARATOR
Intervention: Placebo plus gemcitabine and erlotinib
Number of subjects: 607
Study: 16450017

Group type: EXPERIMENTAL
Intervention: Combined folic acid 2.5 mg, vitamin B6 50 mg, and vitamin B12 1 mg daily
Number of subjects: 5522

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5522
Study: 14998785

Group type: EXPERIMENTAL
Intervention: Exercise after antecedent hypoglycemia in men
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Exercise after antecedent hypoglycemia in women
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Endogenous glucose production (EGP) in men after antecedent hypoglycemia
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Endogenous glucose production (EGP) in women after antecedent hypoglycemia
Number of subjects: 14
Study: 11529805

Group type: EXPERIMENTAL
Intervention: Home-based nurse intervention (INT) consisting of 16 home visits from birth to 18 months
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 100
Study: 9242313

Group type: EXPERIMENTAL
Intervention: Mebendazole (500 mg single dose)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Pyrantel (Combantrin)
Number of subjects: 103
Study: 8466836

Group type: EXPERIMENTAL
Intervention: Co-operative Logo environment (N = 30)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Individualised Logo environment (N = 24)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Non-treatment control group (N = 29)
Number of subjects: 83
Study: 3552364

Group type: EXPERIMENTAL
Intervention: Actrapid-Monotard
Number of subjects: 18

Group type: COMPARATOR
Intervention: Actrapid-Protaphane
Number of subjects: 18
Study: 30431467

Group type: EXPERIMENTAL
Intervention: Cuídalos sexual communication intervention
Number of subjects: 660

Group type: COMPARATOR
Intervention: Physical activity program (control)
Number of subjects: 660
Study: 29035602

Group type: EXPERIMENTAL
Intervention: Dextrose (1 g/kg body mass)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Modified Amylomaize-7 (1 g/kg body mass)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Flavored water placebo
Number of subjects: 10
Study: 28003294

Group type: EXPERIMENTAL
Intervention: Non-operative management (NOM) with antibiotic therapy alone
Number of subjects: 220

Group type: COMPARATOR
Intervention: Operative management with prophylactic antibiotics and appendicectomy
Number of subjects: 220
Study: 24107844

Group type: EXPERIMENTAL
Intervention: Rapamycin treatment
Number of subjects: 40
Study: 22578337

Group type: EXPERIMENTAL
Intervention: Becaplermin gel (Regranex(®))
Number of subjects: 59

Group type: COMPARATOR
Intervention: Duoderm Hydrogel™
Number of subjects: 59
Study: 19242336

Group type: EXPERIMENTAL
Intervention: Postinsertion ultrasound (US) inspection of the ipsilateral neck (n = 151)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Usual practice (control group, n = 149)
Number of subjects: 300
Study: 17336967

Group type: EXPERIMENTAL
Intervention: Injectable DMPA
Number of subjects: 14
Study: 15966757

Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg/day
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Modafinil 800 mg/day
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cocaine 20 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Cocaine 40 mg
Number of subjects: 12
Study: 11665349

Group type: EXPERIMENTAL
Intervention: Fluoride varnish (Duraphat, Colgate‐Palmolive Co.) applied at baseline and after four months
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control group (no professional fluoride applications)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Fluoride varnish (Duraphat, Colgate‐Palmolive Co.)
Number of subjects: 142
Study: 9853201

Group type: EXPERIMENTAL
Intervention: 30 micrograms ethinylestradiol plus 150 micrograms desogestrel
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: 30 micrograms ethinylestradiol plus 75 micrograms gestodene
Number of subjects: 595
Study: 8209393

Group type: EXPERIMENTAL
Intervention: Traditional medical practitioners delivering family planning services after training for two years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control villages (no traditional medical practitioners involved)
Number of subjects: 0
Study: 2556433

Group type: EXPERIMENTAL
Intervention: Serotype 1 reassortant vaccine
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Serotype 2 reassortant vaccine
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Serotype 3 (rhesus rotavirus) vaccine
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Bivalent preparation (serotypes 1 and 3) vaccine
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: IgA ELISA
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: IgG ELISA
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: PRNA
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: IgM ELISA
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Complement fixation (CF)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: IgA ELISA and PRNA
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: CF
Number of subjects: 116
Study: 4826996

Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy plus pyloroplasty
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Selective vagotomy without pyloroplasty
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both types of vagotomy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Incomplete selective vagotomy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Complete selective vagotomy
Number of subjects: 40
Study: 31455471

Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation
Number of subjects: 206
Study: 28543302

Group type: EXPERIMENTAL
Intervention: TOBY therapy plus treatment-as-usual (n=41)
Number of subjects: 80

Group type: COMPARATOR
Intervention: treatment-as-usual (n=39)
Number of subjects: 80
Study: 25384463

Group type: EXPERIMENTAL
Intervention: Shape Up+Internet program+incentives (SII)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Shape Up+Internet behavioral program (SI)
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Shape Up+Internet program+group sessions (SIG)
Number of subjects: 268
Study: 24289799

Group type: EXPERIMENTAL
Intervention: Ultrasound (US)‐guided needling combined with leukocyte‐depleted (pure) PRP
Number of subjects: 80

Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 80
Study: 21236483

Group type: EXPERIMENTAL
Intervention: Aliskiren plus amlodipine (150 mg aliskiren plus 5 mg amlodipine)
Number of subjects: 1254

Group type: COMPARATOR
Intervention: Aliskiren (150 mg)
Number of subjects: 1254

Group type: COMPARATOR
Intervention: Amlodipine (5 mg)
Number of subjects: 1254

Group type: EXPERIMENTAL
Intervention: Combination therapy (300 mg aliskiren plus 10 mg amlodipine)
Number of subjects: 1254
Study: 19120336

Group type: EXPERIMENTAL
Intervention: Formulation with 0.5% benzyl nicotinate (BN) and 10% fat
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Formulation with 0.3% betamethasone valerate (BV) and low fat content
Number of subjects: 0

Group type: COMPARATOR
Intervention: Formulations with higher fat content (not specified)
Number of subjects: 0
Study: 17538086

Group type: EXPERIMENTAL
Intervention: Temsirolimus (25 mg intravenous weekly)
Number of subjects: 626

Group type: EXPERIMENTAL
Intervention: Combination therapy (15 mg temsirolimus weekly + 6 million U interferon alfa three times weekly)
Number of subjects: 626

Group type: COMPARATOR
Intervention: Interferon alfa (3 million U subcutaneously three times weekly, increasing to 18 million U)
Number of subjects: 626
Study: 14742392

Group type: EXPERIMENTAL
Intervention: Prophylactic intravenous ephedrine
Number of subjects: 390
Study: 15598111

Group type: EXPERIMENTAL
Intervention: Explicit social comparisons
Number of subjects: 0

Group type: COMPARATOR
Intervention: Implicit social comparisons
Number of subjects: 0
Study: 10360849

Group type: EXPERIMENTAL
Intervention: Naloxone (0.8 mg/15 min followed by 0.4 mg/h) + Ketamine (0.3 mg x kg(‐1) x 15 min(‐1) followed by 0.3 mg x kg(‐1) x h(‐1))
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Placebo + Ketamine (0.3 mg x kg(‐1) x 15 min(‐1) followed by 0.3 mg x kg(‐1) x h(‐1))
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo + Placebo
Number of subjects: 25
Study: 7560572

Group type: EXPERIMENTAL
Intervention: 10 percent povidone-iodine
Number of subjects: 120

Group type: COMPARATOR
Intervention: 0.2 percent chlorhexidine
Number of subjects: 120

Group type: COMPARATOR
Intervention: sterile water
Number of subjects: 120
Study: 1787282

Group type: EXPERIMENTAL
Intervention: Khitchri and half-strength cow's milk formula after initial rehydration with ORS (group B)
Number of subjects: 69

Group type: COMPARATOR
Intervention: WHO ORS alone for the first 24 hours followed by khitchri and half-strength cow's milk formula (group A)
Number of subjects: 69
Study: 6125164

Group type: EXPERIMENTAL
Intervention: metoprolol (1 mg i.v.)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: oxprenolol (1 mg i.v.)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: propranolol (1 mg i.v.)
Number of subjects: 10
Study: 30654644

Group type: EXPERIMENTAL
Intervention: Guanfacine plus cognitive remediation and social skills training
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo plus cognitive remediation and social skills training
Number of subjects: 28
Study: 29383569

Group type: EXPERIMENTAL
Intervention: Levetiracetam extended-release (ER) tablets
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Levetiracetam ER tablets with food
Number of subjects: 34

Group type: COMPARATOR
Intervention: Levetiracetam immediate-release (IR) tablets
Number of subjects: 34
Study: 27390949

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 8029

Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 8029
Study: 24897906

Group type: EXPERIMENTAL
Intervention: Audiovisual modality training condition
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Visual modality condition
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Auditory modality condition
Number of subjects: 175

Group type: COMPARATOR
Intervention: No-training condition
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Audiovisual condition with rehearsal
Number of subjects: 175
Study: 22554213

Group type: EXPERIMENTAL
Intervention: Nurse-led psycho-education program
Number of subjects: 79

Group type: COMPARATOR
Intervention: Usual psychiatric outpatient care
Number of subjects: 79
Study: 20181806

Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/d)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Fish oils (4 g/d)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Combination treatment (Atorvastatin + Fish oils)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 18157417

Group type: EXPERIMENTAL
Intervention: Mechanical aorto-saphenous anastomosis
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional anastomosis
Number of subjects: 12
Study: 16046530

Group type: EXPERIMENTAL
Intervention: T-cell depletion (TCD) plus cyclosporine (CSA)
Number of subjects: 404

Group type: COMPARATOR
Intervention: Unmodified grafts with CSA plus methotrexate (M/C)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: T-cell depletion (TCD)
Number of subjects: 404
Study: 12354684

Group type: EXPERIMENTAL
Intervention: Lunch cue (thinking about what they had eaten for lunch)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lunch today cue
Number of subjects: 0

Group type: COMPARATOR
Intervention: No cue (free thought condition)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lunch yesterday cue
Number of subjects: 0
Study: 10077348

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triiodothyronine administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of GH and triiodothyronine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7554199

Group type: EXPERIMENTAL
Intervention: Warfarin treatment group
Number of subjects: 516

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 516
Study: 31519475

Group type: EXPERIMENTAL
Intervention: Clobazam (20 mg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Clobazam (40 mg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Clobazam and Stiripentol
Number of subjects: 13

Group type: COMPARATOR
Intervention: Clobazam
Number of subjects: 13
Study: 28410510

Group type: EXPERIMENTAL
Intervention: Tourniquet application after local forearm warming (active warming group; n=36)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Tourniquet application alone (passive warming group; n=36)
Number of subjects: 72
Study: 26568899

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Diabetes Education and Support
Number of subjects: 207
Study: 23860421

Group type: EXPERIMENTAL
Intervention: Flexible pylon system
Number of subjects: 28
Study: 21224820

Group type: EXPERIMENTAL
Intervention: Uncoated ECC-set (group A)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Heparin-coated ECC-set (group B)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Heparin-coated ECC-set (group C)
Number of subjects: 63

Group type: COMPARATOR
Intervention: All groups (A, B, C)
Number of subjects: 63
Study: 19499468

Group type: EXPERIMENTAL
Intervention: King LT
Number of subjects: 27

Group type: COMPARATOR
Intervention: Combitube
Number of subjects: 27
Study: 16995587

Group type: EXPERIMENTAL
Intervention: Low-dose ACTH test (LDT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard-dose ACTH test (SDT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Budesonide (400 μg or 600 μg daily doses)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 24-hour urinary free cortisol excretion
Number of subjects: 30
Study: 14758580

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 11240872

Group type: EXPERIMENTAL
Intervention: 5% halothane
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 8% sevoflurane
Number of subjects: 21
Study: 9292541

Group type: EXPERIMENTAL
Intervention: RheothRx (poloxamer 188) Injection
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 8038025

Group type: EXPERIMENTAL
Intervention: Cycling at a target heart rate of 100 beats/min
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cycling at a target heart rate of 150 beats/min
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Infusion of atropine (target heart rate 100 beats/min)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Additional infusion of adrenaline and noradrenaline
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control state without cycling
Number of subjects: 6
Study: 3524645

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation (both intravenous and oral)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Non-supplemented group
Number of subjects: 17
Study: 30590590

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2702
Study: 28279428

Group type: EXPERIMENTAL
Intervention: Nadroparin (2850 IE anti‐Xa=0.3ml daily subcutaneous self-injection)
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: Fondaparinux (2.5mg=0.5ml daily subcutaneous self-injection)
Number of subjects: 467

Group type: COMPARATOR
Intervention: Control (no thromboprophylaxis)
Number of subjects: 467
Study: 25991154

Group type: EXPERIMENTAL
Intervention: Telekit telehealth system
Number of subjects: 60
Study: 23469888

Group type: EXPERIMENTAL
Intervention: 20 mg single oral dose of memantine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21255399

Group type: EXPERIMENTAL
Intervention: Social-skills training and parental training plus standard treatment
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 52
Study: 19150264

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 17062805

Group type: EXPERIMENTAL
Intervention: MedGem (MG)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Delta Trac II (DT)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MedGem (MG) sitting position
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MedGem (MG) supine position
Number of subjects: 100